Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Merlin C. Thomas
Diabetes & Metabolism (2017) Vol. 43, pp. 2S20-2S27
Closed Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Therapeutic peptides: current applications and future directions
Lei Wang, Nanxi Wang, Wenping Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 1155
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Jordan Rowlands, Julian Ik‐Tsen Heng, Philip Newsholme, et al.
Frontiers in Endocrinology (2018) Vol. 9
Open Access | Times Cited: 235
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
Annabelle M. Warren, Søren Tang Knudsen, Mark E. Cooper
Expert Opinion on Therapeutic Targets (2019) Vol. 23, Iss. 7, pp. 579-591
Closed Access | Times Cited: 216
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M. Shaman, Stephen C. Bain, George L. Bakris, et al.
Circulation (2021) Vol. 145, Iss. 8, pp. 575-585
Open Access | Times Cited: 165
Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
Kevin Yau, Atit Dharia, Ibrahim Alrowiyti, et al.
Kidney International Reports (2022) Vol. 7, Iss. 7, pp. 1463-1476
Open Access | Times Cited: 130
Mechanisms of podocyte injury and implications for diabetic nephropathy
Federica Barutta, Stefania Bellini, Gabriella Gruden
Clinical Science (2022) Vol. 136, Iss. 7, pp. 493-520
Open Access | Times Cited: 115
Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammation
Karly C. Sourris, Yi Ding, Scott Maxwell, et al.
Kidney International (2023) Vol. 105, Iss. 1, pp. 132-149
Open Access | Times Cited: 48
GLP-1 Receptor Agonists and Kidney Protection
Eulalia Greco, Giuseppina Russo, Annalisa Giandalia, et al.
Medicina (2019) Vol. 55, Iss. 6, pp. 233-233
Open Access | Times Cited: 129
Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets
Jonatan Barrera‐Chimal, Frédéric Jaisser
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S1, pp. 16-31
Open Access | Times Cited: 129
GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists
José Luis Górriz, María José Soler, Juan F. Navarro‐González, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 4, pp. 947-947
Open Access | Times Cited: 118
Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
Francesco Prattichizzo, Paola de Candia, Antonio Ceriello
Metabolism (2021) Vol. 120, pp. 154799-154799
Closed Access | Times Cited: 54
Glucose and Blood Pressure-Dependent Pathways–The Progression of Diabetic Kidney Disease
Devang M. Patel, Madhura Bose, Mark E. Cooper
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 2218-2218
Open Access | Times Cited: 50
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)
Sho Furusawa, Hiroshi Nomoto, Chiho Oba‐Yamamoto, et al.
Endocrine Journal (2024) Vol. 71, Iss. 6, pp. 603-616
Open Access | Times Cited: 7
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Silvia Tempia Valenta, Alba Nicastri, Federica Perazza, et al.
Current Treatment Options in Psychiatry (2024)
Closed Access | Times Cited: 6
Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2018) Vol. 45, Iss. 2, pp. 110-121
Closed Access | Times Cited: 49
Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Sanjay Kalra, Ashok Kumar Das, Rakesh Sahay, et al.
Diabetes Therapy (2019) Vol. 10, Iss. 5, pp. 1645-1717
Open Access | Times Cited: 45
The future of new drugs for diabetes management
Clifford J. Bailey, Caroline Day
Diabetes Research and Clinical Practice (2019) Vol. 155, pp. 107785-107785
Open Access | Times Cited: 44
Albuminuria‐lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo‐controlled study
Suvanjaa Sivalingam, Victor Wasehuus, Viktor Rotbain Curovic, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 1, pp. 54-64
Open Access | Times Cited: 15
Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus
Chih‐Chun Chuang, Kai Wang, Chao‐Kai Chang, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 3, pp. 540-546
Open Access | Times Cited: 5
Novel therapies for diabetic kidney disease
David Z.I. Cherney, George L. Bakris
Kidney International Supplements (2017) Vol. 8, Iss. 1, pp. 18-25
Open Access | Times Cited: 41
Preventing and treating kidney disease in patients with type 2 diabetes
Pierre Delanaye, André Scheen
Expert Opinion on Pharmacotherapy (2018) Vol. 20, Iss. 3, pp. 277-294
Open Access | Times Cited: 38
The Future of Glucagon-Like Peptide-1 Receptor Agonists In Cardiovascular–Kidney–Metabolic Diseases
Matias Trillini, Trond Jenssen, William P. Martin, et al.
Nephrology Dialysis Transplantation (2025)
Closed Access
Syringaldehyde Alleviates Cardiac Hypertrophy Induced by Hyperglycemia in H9c2 Cells Through GLP-1 Receptor Signals
Yingxiao Li, Chao-Tien Hsu, Tingting Yang, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 1, pp. 110-110
Open Access
Glucagon‐Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26‐Week Prospective Observational Real‐Life Study
Alfredo Vozza, Sara Volpe, Carlo Custodero, et al.
Journal of Diabetes Research (2025) Vol. 2025, Iss. 1
Open Access
Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial
Annemarie B. van der Aart‐van der Beek, Lindsay E. Clegg, Robert C. Penland, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2493-2498
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top